Form 4: New Enterprise Associates Acquires Warrants in NeueHealth, Inc.

New Enterprise Associates 17, L.P. reports the acquisition of warrants to purchase 123,729 shares of NeueHealth, Inc. common stock.

Summary

• New Enterprise Associates 17, L.P. filed a Form 4 disclosing the acquisition of warrants for NeueHealth, Inc. common stock on April 8, 2024.
• The warrants, granting the right to buy 123,729 shares, were acquired pursuant to a Warrantholders Agreement dated April 8, 2024.
• The warrants will be issued on the first business day following the conclusion of the 10 calendar day period after the distribution of the letter required to be mailed by the Issuer to its shareholders pursuant to Section 312.05 of the NYSE Listed Company Manual.
• The warrants are exercisable at any time after issuance and prior to the close of business on the fifth anniversary of the Closing Date.
• The price of the warrant is $0.01.
• The securities are directly held by New Enterprise Associates 17, L.P. and are indirectly held by NEA Partners 17, L.P., NEA 17 GP, LLC and the individual managers of NEA 17 GP.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The acquisition of warrants by a reputable firm like NEA suggests confidence in the company's future, but it's a standard transaction and doesn't necessarily indicate a major shift in the company's prospects.

Positives

• The acquisition of warrants by a significant investor like New Enterprise Associates could be seen as a positive signal for NeueHealth, Inc.

Risks

• The value of the warrants is dependent on the future performance of NeueHealth, Inc.'s stock price.
• The exercise of the warrants could dilute existing shareholders' equity.

Future Outlook

The warrants are exercisable at any time after issuance and prior to the close of business on the fifth anniversary of the Closing Date, indicating a long-term investment perspective from New Enterprise Associates.

Industry Context

Form 4 filings are standard disclosures for significant shareholders, providing transparency into their investment activities. This filing indicates continued investment interest from a major venture capital firm in the healthcare technology space.

Comparison to Industry Standards

• NEA is a well-known venture capital firm with a history of investing in healthcare companies, including companies like Flatiron Health (acquired by Roche) and CloudHealth Technologies (acquired by VMware).
• The warrant structure is a common mechanism for venture capital firms to gain exposure to potential upside in portfolio companies.

Stakeholder Impact

• Shareholders may see this as a positive sign of investor confidence.
• The exercise of warrants in the future could dilute existing shareholders' equity.

Next Steps

• NeueHealth, Inc. will need to distribute a letter to its shareholders pursuant to Section 312.05 of the NYSE Listed Company Manual.
• The warrants will be issued on the first business day following the conclusion of the 10 calendar day period after the distribution of the letter required to be mailed by the Issuer to its shareholders pursuant to Section 312.05 of the NYSE Listed Company Manual.

Key Dates